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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre    over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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AU  African Union 
AU-IBAR African Union Inter-African Bureau for Animal Resources  
BBRSC  Biotechnology and Biological Sciences Research Council  
BMGF  Bill and Melinda Gates Foundation 
CaPV  Capripox virus 
CVO  Chief Veterinary Officer 
DIVA  Differentiate infected from vaccinated animals  
DVS  Director Veterinary Services 
ELISA  Enzyme-linked immunosorbent assay 
FAO  Food and Agriculture Organization of the United Nations  
GPV  Goat pox virus (also shown sometimes as GTPV) 
IAEA  International Atomic Energy Agency of the United Nations  
IFAT  Indirect fluorescent antibody test 
IM  Intramuscular 
KS-1  Kenyan sheep pox vaccine strain 
KSGV  Kenyan sheep and goat pox virus 
LSD  Lumpy skin disease 
LSDV  Lumpy skin disease virus 
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NGO  Non-governmental organization 
OIE  World Animal Health Organization 
PANVAC Pan African Vaccine Center 
PCR  Polymerase chain reaction 
SGP  Sheep and goat pox 
SPV  Sheep pox virus (also SPPV) 
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Sheep and Goat Pox | Monograph 22 








Etiology and relevance 
Sheep and goat pox (SGP) is probably one of the most serious infectious diseases of small ruminants in parts of 
Africa and Asia where the diseases occur. Sheep pox and goat pox are viral diseases of sheep and goats 
characterized by fever, generalized papules or nodules, vesicles (rarely), internal lesions (particularly in the 
lungs), and death. The two diseases result from infection with strains of capripoxvirus, all of which can infect 
sheep and goats. Despite the fact that most of the strains studied to date cause more severe clinical disease in 
either sheep or goats, some of the isolates are equally pathogenic in both species. 
Sheep pox virus (SPV) and Goat pox virus (GPV), along with lumpy skin disease virus are members of the viral 
genus Capripoxvirus, in the family Poxviridae. SPV and GPV cannot be distinguished from each other with 
serological technique, and used to be considered strains of a single virus. Through genetic sequencing it has now 
been demonstrated that these viruses are distinct, but recombination can occur between them. Recombinant 
strains usually have intermediate host specificity. 
As for other poxviridae, SPV and GPV are double-stranded DNA virus, with a large size genome, which has been 
extensively exploited in generating recombinant multivalent vaccines by inserting foreign viral genes. They are 
also very stable viruses. 
 
Epidemiology and transmission 
Sheep and goat capripoxviruses cause diseases only in these two species, with some variation in the 
susceptibility of different breeds and strains of sheep and goats to the two viruses. 
The disease is prevalent in Africa North of the Equator, although it is also present in Tanzania, the Middle East, 
Turkey, Iran, Iraq, Afghanistan, Pakistan, Nepal, India, China, Bangladesh, Vietnam and Chinese Taipei. 
SPV and GPV are often transmitted by the respiratory route during close contact, and may also enter the body 
through other mucous membranes or abraded skin. These viruses can be found in saliva, nasal and conjunctival 
secretions, milk, urine and feces, as well as in skin lesions and their scabs. The viruses can also be spread on 
fomites or transmitted mechanically by insects such as flies. There is no evidence that SPPV can replicate in 
arthropod vectors. 
Transmission of infection occurs by contact through abraded skin and inhalation, or mechanically by flies. 
Chronically infected carriers do not occur in sheep and goat pox. 
Sheep and goat pox are economically important in countries where the diseases occur, due to mortality and high 
morbidity. Economic losses result from decreased milk production, damage to the quality of hides, as seen in 
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Ethiopia, and wool, as well as other production losses. Sheep and goat pox can limit trade and prevent the 
development of intensive livestock production. They may also prevent new breeds of sheep or goats from being 
imported into endemic regions 
 
Clinical signs 
The clinical signs vary from mild to severe, depending on the animal’s age, breed, immunity and other factors, 
with possibility of inapparent infections. The course of the disease in sheep and goat are similar, with first signs 
often including fever, depression, rhinitis, conjunctivitis and lacrimation. Cutaneous lesions develop after 
–J or 2 days, and they progress through the macular, papular, vesicular and pustular stages until scabs are 
formed. Lesions are not only on the skin: mucosae of the mouth, anus, and prepuce or vagina are also affected 
and may become necrotic. In animals that survive acute phase, the papules become necrotic from vascular 
thrombosis and ischaemic necrosis. During healing, they are susceptible to fly strike. Secondary bacterial 
infections, including pneumonia, are common, and death can occur at any stage of the disease. Recovery can be 
slow if the animal was severely affected. 
 
Diagnostics 
Clinically a presumptive diagnosis of the disease can be made based on highly characteristic clinical signs of 
Sheep and goat pox, including full–thickness skin lesions and enlarged lymph nodes; although mild disease may 
be difficult to diagnose and can be confused with parapoxvirus causing orf or urticaria from multiple insect bites. 
At laboratory level the identification of the agent can be conducted through genome detection through PCR, 
electron microscopy of biopsy or crusts, and virus isolation. There is also the antigen ELISA that has been 
described. Capripoxvirus antigen and inclusion bodies may also be seen in stained cryostat or paraffin sections of 
biopsy or post-mortem lesion material. Serological tests include virus/serum neutralisation (golden standard test 
for serology), indirect fluorescent antibody test, capripox antibody ELISA and seldom Western Blot. Most 
serological tests however would not differentiate between different capripox. 
 
Control 
If sheep or goat pox occurs in a previously free country, eradication is usually by slaughter of all infected and in-
contact animals. Animals and movement controls should be implemented. 
The most commonly used control  strategy is through  vaccination with live attenuated  vaccines. All  the 
commercially available vaccines for SP and GP are live attenuated, prepared with a limited number of strains. 
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Most of the vaccine strains have been derived from local pathogenic strains isolated in different parts of the 
world and by passage in cell culture or embryos. 
Inactivated vaccines had been developed but are almost not used as they give, at best, only short-term 
immunity. 
In African the Kenyan strain, KSGP (also called KS-1 024) has been used extensively for the control of sheep and 
goat pox. Isolated from sheep and initially believed to be a sheep pox virus, the KSGP has been shown through 
molecular methods to be actually a lumpy skin disease virus. The sheep pox Romania strain is widely used in the 
Middle East and India, while many other strains are used in different affected regions. 
One multivalent vaccine, consisting of SGP Romania strain and PPR is currently commercially available in Africa 
by MCI Santé animale. 
Because of the large size of poxviridae genomes, several research groups have worked in generating 
recombinant vector virus vaccines, where capripox non-essential genes have been replaced by foreign viral 
genes, therefore generating  multivalent vaccines. But to date  none of these vaccines have been 
commercialised. 
While research on the use of capripox as vector for the expression of foreign genes is still ongoing, opportunities 
for generating safer attenuated vaccines by knocking out virulent genes but maintaining the immunogenicity are 
been explored. The technology could also be used to generate DIVA vaccines. 
In Africa and Asia there is a need to increase the vaccination cover to SP and GP in poor livestock communities, 
who depend on their small ruminants for their livelihood. With the global PPR eradication strategy, through 
which large PPR vaccination campaigns will be taking place, multivalent vaccines including PPR and SGP vaccine 
could provide a great opportunity to widely control sheep and goat pox in regions that otherwise wouldn’t have 
had access to the vaccines. 
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Although initially regarded as two entities, sheep and goat pox are now considered to be a single disease entity 
(5) caused by a pox virus. Early reports of goat pox date around 200 AD. Sheep pox virus (SPPV) and goat pox 
virus (GTPV) belong to the family Poxviridae, the subfamily Chordopoxvirinae and the genus Capripoxvirus. The 
third species of this genus is lumpy skin disease virus (LSDV) (15). All three contain double-stranded DNA 
genomes approximately 150 kb in size (Figure 1). 
The 3 capripox viruses share a high degree of sequence homology, with 96% identity between SPPV and GTPV, 
and 97% identity between LSDV and both GTPV and SPPV genomes, suggesting that GTPV and SPPV are derived 
from a common LSDV ancestor (4). The genomes of all three species encode for at least 147 genes. The genomes 
of the capripox viruses include a large number of nonessential regions which are often targeted for inserting 




Figure 1: Capripox virion: Enveloped, brick-shaped, 300×270x200nm. The linear, dsDNA genome is about 
154kb. The surface membrane displays surface tubules or surface filaments. Two distinct infectious virus 
particles exists: the intracellular mature virus (IMV) and the extracellular enveloped virus (EEV);  
http://viralzone.expasy.org/all_by_species/152.html 
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There are two antigenic forms of capripoxvirus, the intact virion covered in short tubular elements, and the 
intact virion additionally covered in a host-cell-derived membrane (Figure 1). The latter is the form usually 
produced by the infected animal, whereas the former is that seen when virus is produced by freeze–thawing 
infected tissue culture (15). The significance of these form for live or inactivated vaccines is discussed in section 
6. 
Although sheep pox and goat pox are distinct viruses, recombination can occur between them. There are data 
showing that SPPV or GTPV strains may recombine in the field (6). The viruses cannot be distinguished from each 
other with current serological techniques. Only one serotype exists, which encompasses the two viruses. They 
show different levels of host adaptation for either sheep or goats in different parts of the world. The various 
host-adapted strains are indistinguishable serologically but molecular studies have revealed differences. The 
viruses are thought to have prolonged survival in the environment; they can remain infectious for up to six 




Susceptible animal species 
Sheep and goat capripoxviruses cause disease only in these two species. Many SPV isolates are specific for 
sheep, and many GPV strains are specific for goats, but some strains of these viruses readily affect both species. 
Infections have not been reported in wild ungulates (5,6,10). 
Virtually all of the known species of goats and sheep from different parts of the world are susceptible to host- 
specific and other strains of the virus. Most strains cause more severe clinical disease in only one species. Native 
breeds in endemic areas are far less susceptible than introduced breeds of European or Australian origin – 
morbidity and mortality may approach 100% (6,9,10). 
Only local lesions may follow the inoculation of some of the well adapted, host-specific strains in the alternative 
host, such as a host-adapted sheep pox into goats or vice versa. Of some of the viruses found in goats, Kenyan 
and Yemen isolates, as well as an Oman sheep isolate, infect sheep and goats equally. Usually, Middle East and 
Indian isolates are host specific and do not infect sheep (4). 
Difference in sheep and goats breed specificity seems also to be occurring with SGP. It appears also that the host 
preference shown by different strains is due to their adaptation to either goats or sheep in a restricted 
geographical area. Goat pox is more common and severe in younger animals, lactating females and older 
animals, although it affects goats of all ages, sex and breeds. European breeds are particularly susceptible. (5,12) 
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SPP and GTP are enzootic in Africa North of the Equator, across the Middle East and the Indian subcontinent, 
Iran, Iraq, Russia, Kazakhstan, Kyrgyzstan, Afghanistan, Pakistan, Nepal, Mongolia, China, Bangladesh, Vietnam 
(OIE WAHID) and Chinese Taipei where the first outbreak in Chinese Taipei occurred in 2008 and was eradicated 
by stamping out and movement control. The diseases are also endemic in Turkey and between 2013 and 2015 
four outbreaks occurred in Bulgaria and several outbreaks were reported in Greece. See Figure 2. 
According to the OIE WAHID database, the incidence of SPP in Greece is still continuing in 2015 despite 




Figure 2: Figure 2: Map showing the global distribution of SGP (14) 
 
Transmission 
Transmission is usually by aerosol after close contact with severely affected animals containing ulcerated 
papules on the mucous membranes. Through close contact the transmission is via the respiratory route. The SGV 
and GPV may also enter the body through other mucous membranes. 
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The SP and GP viruses can be found in saliva, nasal and conjunctival secretions, milk, urine and feces, as well as 
in skin lesions and their scabs. Ulcers on the mucous membranes are important sources of virus. 
There is no transmission in the pre-papular stage, e.g. animals early in disease or those dying peracutely. There 
is reduced transmission once papules have become necrotic and neutralising antibody produced (about one 
week after onset). Animals with mild localised infections also rarely transmit disease. 
Some important elements in SGP transmission: 
• Chronically infected carriers do not occur 
• Indirect transmission by contaminated implements, vehicles or products (litter, fodder) occurs 
• Indirect transmission by insects (mechanical vectors) has been established (minor role) 
In endemic areas the morbidity rate of SGP varies between 70 and 90%, while the mortality rate is 5–10%, 
although can approach 100% in imported animals (10). 
 
Immunology of the disease 
Infection with poxviruses evokes both humoral and cell-mediated immune responses (5). With the observation 
that heterologous vaccines do generally work, the relative importance of circulating antibodies versus cytotoxic 
T-lymphocytes in the suppression of the infection is not fully understood. However, it is quite clear that on the 
appearance of circulating anti-viral antibodies, infection subsides in hosts (5). Circulating antibody derived 
through natural infection or vaccination may limit spread of virus in the animal, but it is the cell- mediated 
immune response that eliminates infection (6). Cell-mediated immunity is likely to be the most significant 
component in recovery from infection and in long-term protection, as evidenced by the protection afforded by 
vaccination. The immune status of a previously infected or vaccinated animal cannot be related to serum levels 
of neutralizing antibody (9), and current serological tests are unable to distinguish reliably between susceptible 




The clinical signs vary from mild to severe, depending on the animal’s age, breed, immunity and other factors. 
Inapparent infections also occur. The diseases are more severe in lambs and kids than adults. 
Disease begins with: 
• Sudden onset of fever 
• Discharges from the nose and eyes, and salivation 
• Loss of appetite 
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• Reluctance to move 
• Skin lesions appear in 1-2 days, extending all over the skin, but are most obvious on face, eyelids and 
ears, perineum and tail. Lesions may also be seen on the mucous membranes of the nostrils (Figure 
3a), mouth and vulva 
• Acute respiratory distress 
• Mortality peaks about two weeks after the onset of the skin lesions (Figure 3b) 
• Lesions begin as an area of reddening, progressing over two weeks to a papule, vesicle, pustule with 




Figure 3: a. Nostril exudation and scab linked to SGP infection (source: CSFPH) b. Goat pox 
Skin lesions (photo courtesy Dr. C Ayebazibwe, Entebbe, Uganda) 
 
Lesions that develop on the mucous membranes and internal organs may cause systemic signs. In some cases, 
these symptoms may precede the onset of skin lesions by a day or two. Lesions in the mouth, nares, eyes or 
eyelids can cause salivation or inappetence, as well as rhinitis, conjunctivitis or blepharitis with mucopurulent 
discharges (12). 
Nodules in the intestines can cause diarrhea. Depression and emaciation may be seen in some animals. 
Abortions can occur but are not common. Some breeds of sheep can die of acute disease before the 
characteristic skin lesions appear. 
Capripox lesions can take several weeks to heal, and may leave permanent scars on the skin. During healing, 
they are susceptible to fly strike. Secondary bacterial infections, including pneumonia, are common, and death 
can occur at any stage of the disease. Recovery can be slow if the animal was severely affected. 
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In animals that survive the acute disease, the following can be observed: 
• papules become necrotic from vascular thrombosis and ischaemic necrosis 
• papules form scabs in the next 5–10 days, which persist for up to 6 weeks, leaving small scars 
• skin lesions are susceptible to fly strike 
• secondary pneumonia is common 
• anorexia is unusual unless mouth lesions physically interfere with feeding 




The incubation period for sheep and goat pox is 8–13 days (10,12). The diagnosis could be based on clinical signs 
and lesions, as well as laboratory diagnosis. 
 
Clinical Diagnosis 




The differential diagnoses include contagious ecthyma (contagious pustular dermatitis), bluetongue, 
dermatophilosis/ streptothricosis, mange (e.g., psoroptic mange/sheep scab), photosensitization or urticaria, 
PPR, parasitic pneumonia, multiple insect bites and caseous lymphadenitis. 
 
Pathology and post-mortem diagnosis 
Gross pathology and histopathology can be used for SGP. The following lesions are characteristic of SGP (10): 
• Skin lesions: congestion, hemorrhage, oedema, vasculitis and necrosis. All the layers of epidermis, 
dermis and sometimes musculature are involved. 
• Lymph nodes draining infected areas: enlargement (up to eight times normal size), lymphoid 
proliferation, oedema, congestion, hemorrhage. 
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• Pox lesions: on mucous membranes of the eyes, mouth, nose, pharynx, epiglottis, trachea, on the 
rumenal and abomasal mucosae, and on the muzzle, nares, in the vulva, prepuce, testicles, udder, and 
teats. Lesions may coalesce in severe cases. 
• Lung lesions: severe and extensive pox lesions, focal and uniformly distributed throughout the lungs; 
congestion, oedema, focal areas of proliferation with necrosis, lobular atelectasis. Enlargement, 
congestion, oedema and haemorrhages of mediastinal lymph nodes. 
 
Laboratory diagnosis 
Rapid diagnostic confirmation of the tentative field diagnosis is fundamental for the successful control and 
eradication of SPP in endemic and non-endemic countries. Diagnostic methods are aimed at either identifying 




Figure 4: Diagnostic methods currently used for the detection of a SPP viral antigen or antibodies (6) 
 
Agent identification 
Because of the characteristic morphology of the capripox virus particles which are different to other small 
ruminants’ poxviruses, sheep or goat pox can be tentatively diagnosed by electron microscopy (csfph). Virus 
isolation allows a more definitive diagnosis. A number of cells can be used to isolate SPV and GPV: lamb testis, 





Infective virus Viral antigen 
Serum 
neutralization assay 
IFAT ELISA AGID 
Virus isolation PCR 
Gel-based PCR Real-time PCR Species specific PCR Penside PCR 
PCR method 
(virulent:attenuated 
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appearance of CPE may take 4–12 days, intracytoplasmic inclusions are clearly seen by haematoxylin and eosin 
staining, and antigen can be detected by immunoperoxidase or immunofluorescence staining techniques 
(10,15). 
PCR assays can detect capripoxvirus genomes in tissue samples or cultures, but cannot identify whether the 
virus is SPV or GPV. The two viruses can be distinguished by combining PCR with a restriction fragment length 
polymorphism (RFLP) assay. Recombination between SPV and GPV can complicate identification of the virus 
(12). 
Viral antigens can be detected in tissues of lymph gland biopsy material taken from an early case, by agar gel 
immunodiffusion (AGID). There are also various antigen ELISAs. 
In histopathological slides, capripoxvirus antigen and inclusion bodies may also be seen in stained cryostat or 
paraffin sections of biopsy or post-mortem lesion material. 
 
Antibody detection 
Serology can identify GPV and SPV as capripoxviruses, but cannot distinguish the two viruses from each other. 
Antibodies to capripoxviruses can be found approximately one week after the skin lesions appear. Serological 
tests include virus neutralization, AGID, the indirect fluorescent antibody test (IFA), ELISAs and immunoblotting 
(Western blotting). Virus neutralisation is the most specific serological test, but not sufficiently sensitive since 
immunity to capripox infection is predominantly cell mediated – infected animals may only produce 
undetectable low levels of neutralising antibody. Cross–reactions occur with other viruses in the AGID and IFA 
tests. Western blotting uses P32 antigen of capripoxvirus for reaction with test sera; the assay is sensitive and 
specific, but is expensive and difficult to carry out. 
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Incidence data by country 
Although SGP is very widespread in Africa North of the Equator, there is very limited reporting on the 
occurrence of the disease, due to limited interest in monitoring health status of small ruminants, beside the 
work done through externally funded projects. 
Table 1: Number of SGP outbreaks reported to the OIE between 2005-2015 (Numbers given only for the 
target countries). Source: OIE. 
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Asia 
Bangladesh - - + + + + + + 0 0 - 
India 529 1,389 777 63 105 241 197 116 55 88 - 
Indonesia 0 0 - 0 - - - - - - - 
Myanmar 0 0 - - - - - - 0 0 0 
(Burma)            
Nepal 14 10 2 4 10 8 + 0 0 0 0 
Vietnam 15 + >1 + + + + + 0 0 0 
West Africa 
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Burkina Faso >3 + + + + + + 9 2 6 - 
Ivory Coast +? 0 0 0 0 0 0 0 >1 - - 
Mali 2 3 2 0 0 1 0 0 0 0 - 
Senegal 9 6 4 + 5 7 7 5 10 3 5 
East Africa 
Ethiopia 58 500 179 297 270 310 197 301 342 104 >17 
Kenya 1 0 0 0 ? 0 0 0 0 0 - 
Rwanda - 0 0 0 0 - - ? ? - - 
Tanzania 0 + + 0 0 0 0 0 0 0 3 
Uganda - - - - - - - + + + - 
Southern Africa 
Madagascar 0 0 0 0 0 0 0 0 0 0 - 
Malawi 0 0 0 0 0 0 0 0 - - - 
Mozambique 0 0 0 0 0 0 0 0 0 0 - 
South Africa 0 0 0 0 0 0 0 0 0 0 0 
Zambia - - - - - - - ? 0 0 - 
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2- AU-IBAR: The number of outbreaks reported to AU-IBAR is included in the Pan African Animal Resources Year 
Book. (http://www.au-ibar.org/pan-african-animal-resources-yearbook?showall=&limitstart=) and can be 
seen for the countries of interest in Table 2 below. 
Table 2: Number of SGP outbreaks reported to the OIE between 2005-2015 (Numbers given only for the 
target countries). Source: OIE. 
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail 
 
Country 2005* 2006** 2007 2008 2009 2010*** 2011 2012 2013 2014 2015 
West Africa 
Burkina Faso         4 6  
Ivory Coast            
Mali            
Senegal   5 1 5  7 6 9 2  
East Africa 
Ethiopia    3 5 283 223 428 697 139  
Kenya   6579 
cases 
  855 
cases 
2 4  4  
Rwanda            
Tanzania         1 2  
Uganda            
Southern Africa 
Madagascar            
Malawi            
Mozambique            
South Africa            
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Zambia     1       
 
*AU-IBAR didn’t start yet producing data for SGP 
**No individual country report available; 
***The 2010 results seem to be incorrect as there are incidence reports in countries known to be free of SGP, 





Prevalence data by country 
• Sources: PubMed, and internet engine searches (English and French when applicable). 
• Efforts have been made to include the year of the study, and not the year of the publication. If they are 
known to be different, the year of publication is included in the reference. 
• Note that not all papers have been read in full. In many cases, only the abstracts have been read. Critical 
evaluation of the papers for inclusion has not been conducted. If a review paper included some 
references, the source of the review is mentioned. 
 
ASIA 
The disease has never been reported in Myanmar and Indonesia. 
No (recent) data was found for SGP prevalence in Bangladesh, India, Nepal and Vietnam. 
 
AFRICA 
The disease has never been reported in Madagascar, Malawi, Mozambique, South Africa and Zambia. 
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Year Area Species of animal No. samples 
tested 
% positive Reference 
2006 Oromia National 
Regional State, about 
95 Km Southeast of 
Addis Ababa 




and  in 
goats 
(12.88%) 




North Gondar zone in 
Amhara regional State; 
740km northwest of 
Addis Ababa 
Sheep and goats 631 sheep and 
152 goat 
5.94% Teshome D.  
Austin J Vet Sci 
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Economic and Social Impacts at Global 







SGP is probably the most serious infectious disease of small ruminants in many parts of the world, responsible 
for tangible (direct) and intangible (indirect) economic losses to small ruminant productivity (5). Although direct 
losses through mortality may be low, the disease inflicts substantial losses in terms of reduced productivity and 
lower quality of wool and leather. It poses a major obstacle in the intensive rearing of sheep and goats and also 
greatly hampers international trade. It is suggested that goat pox is the most important of all pox diseases of 
domestic animals causing high mortality in kids and significant economic losses 
In one study performed in Israel, it was found that SPP and GTP, in endemic areas, are associated with significant 
production losses because of reduced milk yield (up to 30 %), high mortality in lambs (95 %), decreased average 
conception rate (32 %) in the year following the outbreak, decreased weight gain, increased abortion rates (3 %), 
damage to wool and hides and increased susceptibility to pneumonia and fly strike (16). 
In India, where the disease is endemic, a survey conducted in Maharashtra state revealed that the disease has a 
major impact on the economy, with average morbidity and mortality rates of 63.5 and 49.5 %, respectively. The 
effect is such that it would take six years for a flock or herd to recover from an outbreak, with average income 
losses up to 30–43 % of the total annual revenue depending on flock type and owners’ actions. Statewide, 
around 5 000 flocks and herds are affected annually, incurring losses in the range of Indian Rupies 107.5 million 
(7). 
In a study conducted in Ethiopia to evaluate the impact of major cattle, sheep and goat diseases impacting on 
the Hides and skins industry, whose exports average a yearly value of $52,160,000 USD, it was found that SGP 
had a prevalence of 5.94%, impacted accordingly to losses incurred by the country in that sector of the economy 
(13) 
In an ILRI report on Animal diseases Impact on the poor, SGP ranks as one of the top ten small ruminants 
diseases, and within the top 20 most important disease in pastoral systems. 
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As part of their disease prioritization effort, the Bill and Melinda Gates Foundation identified SGP as the seventh 
of 14 diseases that negatively impact on poor livestock keepers. The total annual losses to small farmers in Africa 
and South were estimated to be USD 479.90 million and USD 234.30 million respectively (2). 
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Successful control and eradication of SPPV and GTPV relies heavily on early detection of early cases, rapid 
implementation of stamping-out of all infected and in-contact animals, strict movement control, quarantine and 
disinfection. Different sanitary prophylactic measures can be employed in countries previously  free, including 
slaughtering or culling of infected herd if possible, isolation of infected herds and sick animals for at least 45 
days after recovery (OIE disease card). Experience obtained from the FAO Regional Animal Disease Surveillance 
and Control Network for SPP eradication programme in 2000 within North African countries (Maghreb) countries 
demonstrated that a considerable reduction in SPP cases was achieved when the goal for vaccination coverage 
was set between 75 and 90 % (8). 
The most commonly used control measure in enzootic regions is vaccination, generally with the different live 
attenuated vaccines discussed in section 6 of the present document. 
Annual vaccinations using live attenuated SPP vaccines provide good protection and are able to control the 
outbreaks when the minimal coverage of 75 % is reached and maintained (6). Although capripoxviruses are 
considered to be cross-protective, the use of homologous vaccine is generally recommended since there have 
been unsuccessful attempts to protect either goats with sheep capripoxvirus vaccines or sheep with goat 
capripoxvirus vaccines (11). 
Treatment is not effective in the control of SGP; it is more a supportive action aimed at reducing secondary 
bacterial infections and fly strike (9). 
Countries free of the disease may restrict and prevent importation of live sheep and goat from infected 
countries; the OIE Terrestrial animal Code for sheep and goat pox (OIE Code CHAPTER 14.9.) provides guideline 
on importation from infected countries. 
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Disease situation and government policies by country 
Tables 3 and 4 below have been completed with the information received so far from the questionnaires sent to 
the DG and DVS for PPR. This information will be updated and completed once the results from the different 
countries are received. 
Table 3 covers the disease situation (if it is notifiable or not), the presence of official surveillance and/or control 
programs, and the treatment situation. Table 4 refers to the vaccination situation. 
The definitions that were given to the respondents are: 
1Surveillance: is the systematic ongoing collection, collation and analysis of data and the timely dissemination of 
information to those who need to know so that action can be taken. 
2Control: a program which is approved, and managed or supervised by the Veterinary Authority of a country 
for the purpose of controlling a vector, pathogen or disease by specific measures applied throughout that 
country, or within a zone or compartment of that country. 
 
Table 3: Official status, official programs for SGP in the countries of interest 




















Bangladesh Yes Yes, passive Yes - - 
India      
Indonesia      
Myanmar 
(Burma) 
No Yes, passive No No Yes 
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Nepal Yes Yes, passive No No No 
Vietnam Yes Yes, passive No Yes Yes 
AFRICA 
Burkina Faso      
Côte d'Ivoire 
(Ivory Coast) 
Yes Yes, passive but active if 
outbreak 
No - - 
Ethiopia      
Kenya Yes Yes, passive No No No 
Madagascar      
Malawi Yes Yes, passive No N/A N/A 
Mali Yes Yes, passive Yes No No 
Mozambique      
Rwanda - - - - - 
Senegal      
South Africa      
Tanzania Yes Yes, active and passive No No No 
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Table 4: Vaccination for SGP in the countries of interest 

















(cattle, sheep, goats, 
pigs, poultry) 
ASIA 
Bangladesh No Combination. 
Government subsidy, 
farmers pays a service 
charge 
- Goat and sheep 
India     
Indonesia     
Myanmar 
(Burma) 
No - - - 
Nepal No N/A N/A N/A 
Vietnam No Farmers Private 
vaccinators 
Sheep and goats 
AFRICA 
Burkina Faso     
Côte d'Ivoire 
(Ivory Coast) 
- - - - 
Ethiopia     
Kenya No Combination Both Sheep and goats 
Madagascar     
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Malawi No N/A N/A N/A 
Mali No Combination Official Sheep and goats 
Mozambique     
Rwanda - - - - 
Senegal     
South Africa     
Tanzania No Farmer/private Private Goats and sheep 
Uganda No Government Both Goats and sheep 
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Current vaccine types 
In endemic regions, live and inactivated vaccines have been used for the control of capripox. Inactivated 
vaccines give, at best, only short-term immunity, and are therefore not routinely used. There have been several 
publications on recombinant SGP vaccine candidates, but none has reached the commercialization stage. 
MCI Santé animale in Morocco has so far registered the only combination SGP-PPR vaccine, which is already 
being used in a number of African countries. 
All strains of capripoxvirus so far examined share a major neutralization site and will cross protect, although 
homologous strains provide better protection. 
 
Live attenuated SGP vaccines 
The commercially available SPP and GTP vaccines are live attenuated vaccines, prepared with a limited number 
of strains as shown in Tables 5 and 6. 
 
Table 5: Vaccination for SGP in the countries of interest 
Information provided by the questionnaire sent to the DG/DVS as part of this monograph. 
 
Disease Capripox vaccine strain Major animal targeted Comments 
SGP Romania (SPV) Goats & sheep  
RM-65 (SPV)  Used in cattle at x10 the SG dose 
Mysore (GPV)   
Gorgan (GPV)   
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KSGP (KS-1 /O240 ,LSDV)   




While in Africa the KSGP strain is widely used for the production of the SGP vaccine (Table 5), other parts of the 
world use different strains as shown in Table 6. 
The use of the Kenya KSGP (or KS-1/0240) strain for SGP is discouraged in countries free of LSD, since sequencing 
data had identified the virus as a LSD virus (6). 
As stated earlier cross protection between different strains in different ruminant types (sheep, goat or cattle) is 
not always effective: according to the OIE Manual, the KSGP 0240 strain should not be used in Bos taurus breeds 
of cattle (15). 
Live attenuated vaccines have been used for decades in SPP-endemic countries. Sufficiently attenuated and 
tested vaccines are safe (can be used in pregnant animals providing three months of immunity to lambs) and 
effective though some strains may have unacceptably high levels of residual pathogenicity and may cause skin 
lesions and generalised disease in some animals (6,14). Local reaction at the inoculation site and transient raise 
in body temperature are typical of live attenuated poxvirus vaccines and should be accepted as an indicator of 
virus replication, which is required for the production of strong cell-mediated immunity in vaccinated animals 
(14). 
The recommended dose of most commercially available SGP vaccines is 10–2.5 TCID 50. The protective dose of 
live attenuated SGP vaccines depends on the vaccine strain used. Immunity in sheep and goats against capripox 
following vaccination with the KSGP 0240 strain lasts over a year, and will probably provide lifelong protection 
against lethal challenge. Similarly, the Romanian strain gave protection for at least 30 months (15). 
SPV vaccines are thermostable in lyophilised form and only a single immunisation is required. Generally, 
protection provided by live attenuated vaccines lasts 12–23 months and annual vaccinations  are recommended 
(6). 
The Indian IVRI has been involved in developing Vero cell adapted sheep or goat pox vaccine strains which are 
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Table 6: Vaccination for SGP in the countries of interest 
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There are almost no inactivated commercial vaccines. Inactivated SGP vaccines produced from tissue culture are 
almost entirely naked virions, and when used as vaccines do not stimulate immunity to the membrane- bound 
virion (Figure 1). This in part explains the poor success of inactivated capripox vaccines (5).  An additional factor 
is that inactivated vaccines are less effective than live, replicating vaccine virus in stimulating the cell-mediated 
immune response, which is the predominant protective response to poxvirus infection. Dead capripox vaccines 
provide, at best, only temporary, short term protection. 
 
Recombinant SGP vaccines 
Several experimental recombinant vaccines have indeed  been described expressing genes from different 
viruses, including PPR virus, rabies virus, Rift Valley fever virus, bluetongue virus; and with inactivated 
recombinant epsilon toxin of enterotoxaemia (4,6,14). In addition, the development of a subunit vaccine has 
been reported. None of them has been developed for commercial use. In addition, in these vaccines, the 
replicating virus is a genetically modified capripoxvirus and therefore may not be authorised for use in non- 
endemic countries on safety grounds. Novel approaches for the development of recombinant vaccines against 
GPV have been described using Semliki Forest virus as a vaccine vector into which the immunogenic regions for 
GTPV were inserted. This vaccine provided partial protection against GTPV (6). 
Important to note that in some cases where recombinant capripox vector have been described, the intention 
was not always to generate simultaneous protection to sheep or goat pox, but rather as a vaccine exclusively to 
the insert. 
 
Commercial vaccines manufactured in Africa and Asia  
 
A large number of vaccine manufacturers in Africa, Asia and part of Europe produce the sheep or goat pox 
vaccines. The Jordanian manufacturer, JOVAC, exports into African countries. Table 7 below provide lists of 
manufacturers in Asia, North Africa and Europe, while Table 8 provides information on Sub-Saharan Africa 
manufacturers. 
Table 7: The different commercially available SGP vaccines produced in North Africa, Asia and Europe 
(adapted from 12) 
 
Company (Country) Product Name Type Strain/Subtype Adjuvant 
Agrovet (Russia) Sheep Pox vaccine Not 
Available 
NISHI None 
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Biopharma (Morocco) Name Not Available Live Romanian None 




Live   
Dollvet (Turkey) Poxdoll Live SPV None 
FGBI - Federal Centre for Animal 
Health (Russia) 
Sheep Pox Cultyral Dry Live Not Available None 
Hester Biosciences Limited Goat Pox Vaccine Live Uttarkashi None 
Indian Immunologicals Limited (India) Raksha SP Live Romanian (Sheep 
Pox) 
None 
Institut Pasteur d'Algerie (Algeria) Name Not Available Live RM-65 None 
Institute of Animal Health 
and  Veterinary Biologicals 
(India) 
Sheep Pox Vaccine Not 
Available 
Not Available Not 
Available 
Institute of Veterinary 
Preventive Medicine (India) 
Sheep Pox Vaccine Live Ranipet Aluminum 
Hydroxide 
Intervac (PVT) Ltd. (Pakistan) Intervac Sheep Pox Vaccine Live RM/65 None 
Jordan Bio-Industries Center 
(JOVAC) Jordan 
JOVIVAC (Sheep Pox) Live RM-65 None 
 CAPRIVAC (Goat Pox) Live MLV Gorgan None 
 KENYAVAC Live KSGP 0240 None 
Razi Vaccine & Serum Research 
Institute (Iran) 
Goat Pox Vaccine Live Gorgan None 
 Sheep Pox Vaccine Live RM-65 strain None 
Tiankang Biopharmacuetical (China) Orf Live Not Available Not 
Available 
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Vetal Company (Turkey) Poxvac™ Live Not Available None 
Veterinary Research Institute (Malaysia) S/GP-VAC Killed Not Available Alum 
Veterinary Serum and Vaccine 
Research  Institute (Egypt) 
Tissue Culture Sheep 
Pox Vaccine 
Live Not Available Not 
Available 




Table 8: SGP vaccines produced by Sub-Saharan African manufacturers 
 
Vaccine name Manufacturer Hosts Pathogens vaccinated against 





0240 Kenya sheep and goat pox strain of the 
capripox virus 
Sheep and goat 
pox vaccine 
National Veterinary 








KSGP strain; also for SGP 
DERMAPOX LCV Bamako, Mali Sheep and 
goat 
KSGP strain; also for SGP 
CLAVESEC ISRA Senegal Sheep and 
goat 
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Commercial vaccines imported into Africa and Asia 
 
The information summarised in Table 9, is based on a questionnaire send to the Director of Veterinary Services 
office and regulators of the countries of interest. Note that some vaccines might have been imported under DVS 
dispensation, and they are not necessary licensed in the country. 
To the best of our knowledge, none of the target countries, in the exception of South Africa, Zambia and to a 
limited extend Mozambique, practices vaccination. 
Table 9: SGP vaccines imported into the different focus countries 
 

















Bangladesh No - - - - - - 
India        
Indonesia        
Myanmar 
(Burma) 
- - - - - - - 
Nepal - - - - - - - 
Vietnam - - - - - - - 
AFRICA 
Burkina Faso        
Côte d'Ivoire 
(Ivory Coast) 
- - - - - - - 
Ethiopia        
Kenya - - - - - - - 
Madagascar        
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Malawi N/A N/A N/A N/A N/A N/A N/A 
Mali N/A N/A N/A N/A N/A N/A N/A 
Mozambique        
Rwanda - - - - - - - 
Senegal        
South Africa        
Tanzania - - - - - - - 
Uganda        
Uganda Lyopox PPR Romania 






0 0 0 





JOVAC, the manufacturer from Jordan was also sent a questionnaire designed for key importers into the region. 
They confirmed that they export Kenyavac, a SGP vaccine, strain KSGP 0240 to Africa and Asia. They did not 
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Table 10: Target Product Profile (TPP) SGP vaccine – Proposal: 
 
 Attribute Minimum (current available vaccine) Ideal 
1 Antigen Immunogen with protective antigens 
of capripox viruses that protects 
against SGPV infection 
Immunogen capable of providing full 
protection in sheep and goat against 
SGPV infection 
2 Indication for use For active immunization of sheep & 
goats 
For active immunization of sheep, goats 
and all susceptible animals 
3 Recommended species Sheep and goats All capripox susceptible livestock 
4 Recommended dose 2 ml 1 ml or less 





vaccine) or ready to use solution 
6 Route of administration intramuscular SC, Intramuscular or pour on 
7 Regimen - primary 
vaccination 
Single dose Single lifetime dose 
8 Regimen - booster Single annual booster Lifelong immunity after primary 
vaccination 
9 Epidemiological relevance Protection against all geographically 
distinct strains of SGP 
Protection against capripox viruses and 
prevention of virus transmission 
10 Recommended age at first Animals over 3 months: one injection From 1-2 months of age 
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11 Onset of immunity 2-3 weeks following primary 
vaccination 
One week following primary vaccination 
12 Duration of immunity At least 1 year Lifelong immunity 
13 Expected efficacy To prevent disease (morbidity) & 
prevent mortality. 
To prevent infection and transmission. 
No disease & no mortality in vaccinated 
animals after virus challenge. 
14 Expected safety In animals under 6 months of age, a 
transient pyrexia reaction can occur. 
A transient nodular reaction of varying 
importance, may appear at the 
injection site, it progressively 
disappears within 1 to 2 months. Only 
vaccinate pregnant animals on 
emergency. 
No post-vaccinal reactions at any age. 
Safe for pregnant animals. 
No carrier form in vaccinated animals 
15 Withdrawal period Nil Nil 
16 Special requirements for 
animals 
Do not vaccinate un-healthy animals Do not vaccinate un-healthy animals 
DIVA 
17 Special requirements for 
persons 
None None 
18 Package size 50 doses Multiple pack size from 50 doses 
19 Price to end user Not more than $0.50/dose $0.20/dose at end user 
20 Storage condition and shelf- 
life as packaged for sale 
12 months at 4-8° C 24 months 4-8° C and/or 48 hours at 
30° C 
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Overall conclusion for improved SGP control through vaccination 
SGP is one of the major challenges in small ruminants’ production in most parts of Africa and South Asia. In most 
of these regions, small ruminants are owned by the poor livestock keepers and are not often included in national 
disease control programs. The current global effort to eradicate PPR offers a great opportunity to control several 
small ruminants’ diseases such as SGP. Combination PPR-based vaccines should therefore be promoted as much 
as possible in order to take advantage of the big global investment to be likely directed toward PPR eradication. 
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ANNEX 1: Additional data on disease presence and 
incidence 
Reports to OIE on SGP: 
 
When different animal health statuses between domestic and wild animal population are provided, the box is 
split in two: the upper part for domestic animals, and the lower part for wild animals. 
SGP in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam 
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SGP in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal 
 
SGP in Eastern Africa: Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
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SGP in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
 
 
 
 
 
 
